In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

Pneumococcal pneumonia vaccine is under development for the treatment of pneumonia. It is a conjugate vaccine. It is administered through intramuscular as a liquid formulation. It is a new chemical ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

The following is a summary of “A nationwide study of two decades of invasive pneumococcal disease in the Faroe Islands, ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

Healthcare professionals in the U.S. have noticed a significant increase in vaccine hesitancy among their patients, according ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...